-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

903 Early Initiation of Calcineurin Inhibitor Induces CD8+ Transitory Exhausted-like and CD4+ Cytotoxic T Cells, Maintaining Responsiveness to PD-1 Blockade and Contributing to the Development of Chronic Gvhd after Post-Transplant Cyclophosphamide

Program: Oral and Poster Abstracts
Type: Oral
Session: 701. Experimental Transplantation: Basic and Translational: GVHD, GVL and Alloimmunity
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Translational Research
Monday, December 9, 2024: 3:15 PM

Hajime Senjo, MD1,2, Daigo Hashimoto, MD3, Shihori Tsukamoto, MD4*, Keisuke Kojima, MD4*, Shimpei I Kubota, MD, PhD5*, Ayumu Ito, MD, PhD6*, Tomoe Ichiki, MD4*, Satomi Okada, MD4*, Yumika Saito, MD4*, Toru Miyajima, MD7*, Shinpei Harada, MD4*, Wenyu Li4*, Zixuan Zhang4*, Yuta Hasegawa, MD, PhD4*, Hiroyuki Ohigashi, MD, PhD8*, Takahide Ara, MD, PhD4*, Yoshinori Hasegawa, PhD9*, Yoshihiro Inamoto, MD, PhD10, Masaaki Murakami, VMD, PhD5*, Takahiro Fukuda6* and Takanori Teshima, MD, PhD11

1Department of Hematology, Hokkaido University, Kita-Ku, Japan
2Department of Hematology, Kushiro Rosai Hospital, Kushiro, Japan
3Department of Hematology, Hokkaido University, Sapporo, Japan
4Department of Hematology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan
5Molecular Psychoneuroimmunology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
6Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
7Department of Hematology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo, HOK, Japan
8Department of Hematology, Hokkaido University Hospital, Sapporo, HOK, JPN
9Department of Applied Genomics, Kazusa DNA Research Institute, Chiba, Japan
10Department of Blood and Marrow Transplantation and Cellular Therapy, Fujita Health University, Aichi, Japan
11Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan

[Introduction] We have previously reported that early initiation of calcineurin inhibitors from day 0 (early-CNI) induces CD8+ transitory exhausted-like T cells (transitory-Tex-CNIs) and granzyme B+ (GZMB+) CD4+ T cells after mouse allogeneic hematopoietic cell transplantation (allo-HCT) with post-transplant cyclophosphamide (PTCy), while delayed initiation of CNIs from day 5 post-transplant did not induce these populations (Senjo H: 65th ASH annual meeting). In human PTCy-based haploidentical peripheral blood stem cell transplantation (Haplo-PTCy-PBSCT), we confirmed that early-CNI induced transitory-Tex-CNIs and CD74+GZMB+CD4+ cells. Although we previously showed that transitory Tex-CNIs contribute to the development of chronic GVHD (cGVHD) after mouse allo-HCT (Senjo H: Blood 2023), the functions of CNI-induced T cells in human, as well as their contribution to cGVHD, remained to be clarified. In the current study, we explored the phenotype and functions of human transitory Tex-CNIs and CD74+GZMB+ CD4+ T cells, using peripheral blood T cells harvested from patients on day 28 after Haplo-PTCy-PBSCT. We also examined the relationship between the abundance of these cells on day 28 and the development of cGVHD. [Methods] In Haplo-PTCy-PBSCT, tacrolimus (TAC) was initiated either on day -1 (early-TAC; n = 20) or day 5 (late-TAC; n = 20) of the transplantation, and blood samples were prospectively collected following institutional review board approval. For xenograft transplantation, transitory-Tex-CNIs and GZMB+ CD4+ T cells were purified from patients’ peripheral blood on day 28 after Haplo-PTCy-PBSCT with early-TAC. These cells were mixed at a 1:1 ratio and injected into irradiated NOD-SCID-IL2Rγ-/- (NOG) mice. [Results] By comparing scRNA-seq data from T cells on day 28 after Haplo-PTCy-PBSCT with early-TAC to those with late-TAC, we identified Cx3cr1+ Cd16+ Cd8+ cells with higher expression of Gzmb and Mki67 as transitory-Tex-CNIs. We further found that Cd74+ Gzmb+ Cd4+ T-cell cluster induced by early CNIs specifically expressed Crtam, a marker for CD4+ cytotoxic T cells (CD4+ CTLs). Therefore, we annotated this population as CD4+ CTLs. Importantly, scTCR-seq showed that both clusters had markedly less TCR diversity compared to other clusters, suggesting that these clusters were enriched with alloreactive donor T cells that clonally expanded after allo-HCT. As expected, Flow cytometric analysis confirmed that both CX3CR1+CD16+CD8+ transitory-Tex-CNIs and CRTAM+CD74+CD4+ CTLs were significantly increased in the early-TAC group compared to the late-TAC group on day 28. In an in vitro stimulation assay, we found that transitory-Tex-CNIs and CD4+ CTLs purified from patients in the early-TAC group showed higher responsiveness to PD-1 blockade compared to other CD8+ and CD4+ T cells, resulting in higher upregulation of GZMB and Ki67. In a xenograft model, NOG mice transplanted with both transitory-Tex-CNIs and CD4+ CTLs showed significantly lower body wight and reduced tear secretion volume compared to those transplanted with either population alone or with other CD4+ and CD8+ T cells, indicating that CNI-induced CD4+ and CD8+ populations are responsible for the development of cGVHD, as demonstrated in murine models (Senjo H: Blood 2023, Wang Y: JCI 2024). In the prospective cohort analysis, we found that the cumulative incidence of moderate to severe cGVHD at one-year post-transplant was significantly higher in patients treated with early-TAC compared to late-TAC (20.0% vs 0.0%, p=0.048). Additionally, the cumulative incidence of immunosuppressant cessation at two years was significantly lower in the early-TAC group compared to the late-TAC group (61.1% vs 92.6%, p=0.047). In early-TAC group, we found that patients who developed cGVHD had significantly higher proportions of CD8+ transitory-Tex-CNIs and CD4+ CTLs on day 28 compared to those who did not develop cGVHD thereafter (CD8; 20.8% vs 9.0%, p=0.002, CD4; 13.9% vs 2.8%, p=0.001). [Conclusion] We found that human transitory-Tex-CNIs and CD4+ CTLs induced by early-CNI maintain the responsiveness to PD-1 blockade and contribute to the development of chronic GVHD after Haplo-PTCy-PBSCT. These populations could be promising biomarkers for predicting the development of cGVHD. Delayed initiation of CNIs is crucial for tolerance induction after PTCy without inducing these T-cell populations.

Disclosures: Hashimoto: Eisai Co., Ltd.: Honoraria; Daiichi Sankyo Co., Ltd.: Honoraria; Novartis Japan: Honoraria; Chugai Pharmaceutical Co., Ltd.: Honoraria; Nippon Kayaku Co.,Ltd.: Honoraria; Janssen Pharmaceutical K.K.: Honoraria; Astellas Pharma Inc. Japan: Honoraria. Inamoto: Janssen: Honoraria; Meiji Seika Pharma: Honoraria, Research Funding. Teshima: Sanofi: Honoraria; Novartis: Honoraria; Abbvie: Honoraria; Chugai: Honoraria, Research Funding; Symbio: Honoraria; Takeda: Consultancy, Honoraria; Asahi Kasei Pharma: Honoraria, Research Funding; Gilead: Honoraria; Pfizer: Honoraria; AstraZeneca: Honoraria; Astellas: Honoraria, Research Funding; Nippon Kayaku: Honoraria, Research Funding; Sumitomo Pharma: Research Funding; Roche Diagnostics: Consultancy; JCR Pharma: Honoraria, Research Funding; Meiji Seika Pharma: Consultancy, Honoraria; Kyowa-Kirin: Consultancy, Honoraria, Research Funding; Pharma Essentia Japan: Research Funding; Daiichi Sankyo: Honoraria, Research Funding; Fuji Pharma: Honoraria, Research Funding; Janssen: Honoraria; Bristol-Myers Squibb: Honoraria; Eisai: Research Funding; LUCA Science: Research Funding; Otsuka: Honoraria, Research Funding; Shionogi: Honoraria, Research Funding; MSD: Honoraria; Genmab: Honoraria; Nippon Shinyaku: Consultancy, Honoraria.

*signifies non-member of ASH